1. Home
  2. TNXP vs ULBI Comparison

TNXP vs ULBI Comparison

Compare TNXP & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$5.14

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Logo Ultralife Corporation

ULBI

Ultralife Corporation

HOLD

Current Price

$6.29

Market Cap

104.3M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
ULBI
Founded
2007
1990
Country
United States
United States
Employees
142
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
88.0M
104.3M
IPO Year
2008
1995

Fundamental Metrics

Financial Performance
Metric
TNXP
ULBI
Price
$5.14
$6.29
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $44.50
N/A
AVG Volume (30 Days)
★ 929.5K
26.3K
Earning Date
11-09-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 91.75
N/A
EPS
N/A
★ 13.00
Revenue
$13,107,000.00
★ $191,159,000.00
Revenue This Year
$319.65
$17.65
Revenue Next Year
$101.60
N/A
P/E Ratio
★ N/A
$0.47
Revenue Growth
★ 29.85
16.24
52 Week Low
$5.05
$4.90
52 Week High
$20.58
$8.25

Technical Indicators

Market Signals
Indicator
TNXP
ULBI
Relative Strength Index (RSI) 13.33 46.80
Support Level N/A $6.04
Resistance Level $12.99 $6.42
Average True Range (ATR) 0.51 0.23
MACD -0.07 -0.02
Stochastic Oscillator 3.92 27.40

Price Performance

Historical Comparison
TNXP
ULBI

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company also designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

Share on Social Networks: